ACADIA Pharmaceuticals Inc. Blog | Talkmarkets | Page 2
No data available
No data available

People who follow this stock (67)

Latest Posts

About This Stock More About This Stock
ACADIA: From Depression To Schizophrenia
Article By: MoneyShow.com
Wednesday, January 22, 2020 12:19 PM EDT
At the recent JPMorgan conference, ACADIA Pharmaceuticals presented a business update highlighting several catalysts anticipated in 2020.
In this article: ACAD
Read
Stocks Continue To Climb Higher, But Is The Rally Healthy?
Article By: Michael J. Kramer
Thursday, January 9, 2020 10:16 PM EDT
Stocks had another strong day. I wasn’t that thrilled with the rally.
In this article: ACAD, AAPL, IWM, BYND, JD, ROKU
Read
4 Biotech Stocks In Neurology, As Biotechs March On
Article By: Tarun Chandra, CFA
Saturday, December 21, 2019 5:20 PM EDT
In a space of 2-months, biotechs have gone from recording yearly lows in early October, to recording 2019 highs.
In this article: NBIX, ACAD, KRTX, NERV
Read
Stocks Will Try To Push Higher On Quadruple Witching – December 20
Article By: Michael J. Kramer
Friday, December 20, 2019 9:10 AM EDT
S&P 500 futures are pointing to a slightly higher open on December 20.
In this article: BIIB, SPY, NKE, TSLA, NVDA, ACAD
Read
Stocks Are Jumping On December 16 As The Year-End Rally Continues
Article By: Michael J. Kramer
Monday, December 16, 2019 9:24 AM EDT
Markets are rising once again, with the S&P 500 trading higher by about 50 basis points to start.
In this article: ACAD, TSLA, SPY, BA, MU
Read

PARTNER HEADLINES

Latest Tweets for $ACAD

No tweets yet!

$ACAD

Sunday Trio Of Short Ideas
All Things Tech 8/28/2017 3:36:31 AM

100% agreement on $BWLD especially since it has been flat for months in a bullish market with more room to fall.

I disagree with $AMD. If AMD falls below the SMA200, absolutely short, but the Triple Bottom off 12.00 is a cause of concern + a previous ER beat + Q3 ER beat likely & sitting in oversold territory according to (MFI). $SOXX shows a Pennant as well.

$ACAD long-term is down, but short term is up. Above the SMA 20, 50 & 200.

Both AMD & ACAD is big risk little reward in my book unless the Days to Cover is a big enough window. Otherwise just not worth it in my book.

1 to 1 of 1 comments